Publications

Journal Article
Research Support, Non-U.S. Gov't
Ppublish 517 citations
Electronic publication date
September 24, 2013

View on Pubmed.gov 23505071 | View on doi.org 10.1002/ijc.281...

Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.

Search for publications in this journal Int J Cancer - 133(7):1732-42

Abstract

The multikinase inhibitor sorafenib is currently the treatment of reference for advanced hepatocellular carcinoma (HCC). In our report, we examined the cytotoxic effects of sorafenib on HCC cells. We report that the depletion of the intracellular iron stores achieved by using the iron chelator deferoxamine (DFX) strikingly protects HCC cells from the cytotoxic effects of sorafenib. The protective effect of the depletion of intracellular iron stores could not be explained by an interference with conventional forms of programmed cell death, such as apoptosis or autophagic cell death. We also found that DFX did not prevent sorafenib from reaching its intracellular target kinases. Instead, the depletion of intracellular iron stores prevented sorafenib from inducing oxidative stress in HCC cells. We examined the possibility that sorafenib might exert a cytotoxic effect that resembles ferroptosis, a form of cell death in which iron-dependent oxidative mechanisms play a pivotal role. In agreement with this possibility, we found that pharmacological inhibitors (ferrostatin-1) and genetic procedures (RNA interference against IREB-2) previously reported to modulate ferroptosis, readily block the cytotoxic effects of sorafenib in HCC cells. Collectively, our findings identify ferroptosis as an effective mechanism for the induction of cell death in HCC. Ferroptosis could potentially become a goal for the medical treatment of HCC, thus opening new avenues for the optimization of the use of sorafenib in these tumors.

References

No references provided.

Cited by 517 citations (total)

Journal Article

Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma.

Electronic publication date March 6, 2018

Search for publications in this journal Oncotarget

Min Zheng [...] Kun Ping Lu et al.

Hepatocellular carcinoma (HCC) is the sixth most common cancer, but is the second leading cause of cancer deaths, partially due...

Journal Article Review

A Promising Future of Ferroptosis in Tumor Therapy.

Electronic publication date June 29, 2021

Search for publications in this journal Front Cell Dev Biol

Hui Wang [...] Anwen Shao et al.

Currently, mechanisms and therapeutic approaches have been thoroughly studied in various prevalent malignant tumors, such as breast and lung cancer....

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances

Copyright

© 2013 UICC.